Skip to content
GraphTheory.in

Amit Kumar Halder

University of PortoIN
ORCID0000-0002-4818-9047
h-index
22

via OpenAlex

Citations
1,574

via OpenAlex

Publications
123

About

Amit Kumar Halder is a researcher at the University of Porto. With over 70 publications spanning nearly six decades, from 1970 to 2026, his work focuses on computational modeling and prediction in various fields, including medicinal chemistry, catalysis, and sustainable process design.

Research areas

  • Quantitative structure–activity relationship
  • Chemistry
  • Medicine
  • Biology
  • Biochemistry

Publications (123)

Sorted by most cited.

  1. QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

    2021

    View DOI
    54 cites
  2. Turning deep-eutectic solvents into value-added products for CO2 capture: A desirability-based virtual screening study

    2022

    View DOI
    41 cites
  3. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer

    2022

    View DOI
    40 cites
  4. QSAR modelling: a therapeutic patent review 2010-present

    Expert Opinion on Therapeutic Patents1970journal article

    View DOI
    31 cites
  5. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents

    European Journal of Medicinal Chemistry1970journal article

    View DOI
    26 cites
  6. Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms

    2024

    View DOI
    25 cites
  7. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery

    International Journal of Molecular Sciences2021journal article

    View DOI
    21 cites
  8. 21 cites
  9. 21 cites
  10. Analgesic and Anti-inflammatory Activities of Trayodashang Guggulu, an Ayurvedic Formulation

    2022

    View DOI
    20 cites
  11. Advanced in Silico Methods for the Development of Anti- Leishmaniasis and Anti-Trypanosomiasis Agents

    2018

    View DOI
    20 cites
  12. 19 cites
  13. First multi-target QSAR model for predicting the cytotoxicity of acrylic acid-based dental monomers

    2021

    View DOI
    19 cites
  14. Towards the Development of Anticancer Drugs from Andrographolide: Semisynthesis, Bioevaluation, QSAR Analysis and Pharmacokinetic Studies

    2015

    View DOI
    15 cites
  15. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD

    2023

    View DOI
    11 cites
  16. In silico characterization of aryl benzoyl hydrazide derivatives as potential inhibitors of RdRp enzyme of H5N1 influenza virus

    2022

    View DOI
    10 cites
  17. 10 cites
  18. Toxicological evaluation of Artocarpus lacucha ethyl acetate extract: in vitro and in vivo assessment

    2025

    View DOI
    9 cites
  19. Synthesis, Anticancer Activity, SAR and Binding Mode of Interaction Studies of Substituted Pentanoic Acids: Part II

    2021

    View DOI
    9 cites
  20. Ligand-and structure-based drug design of non-steroidal aromatase inhibitors (NSAIs) in breast cancer

    Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment1970book

    View DOI
    8 cites
  21. Designing multi-target drugs for the treatment of major depressive disorder

    Expert Opinion on Drug Discovery2023journal article

    View DOI
    7 cites
  22. Herbal Medicines for the Treatment of Liver Cirrhosis

    2023

    View DOI
    7 cites
  23. Development of Predictive Linear and Non-linear QSTR Models for Aliivibrio Fischeri Toxicity of Deep Eutectic Solvents

    2019

    View DOI
    6 cites
  24. Structural insights into the interactions of repositioning and known drugs for Alzheimer’s disease with hen egg white lysozyme by MM-GBSA

    2024

    View DOI
    5 cites
  25. Structural insights into molecular and cellular level FXR binding potentials of GW4064 and LY2562175 hybrids by multi in silico modelling analyses

    2025

    View DOI
    4 cites
  26. Role of Natural Polysaccharides in the Management of Lifestyle Diseases

    2023

    View DOI
    4 cites
  27. Predicting mito-target interactions for per-and poly-fluoroalkyl compounds: Mapping mitochondrial toxicity on zebrafish voltage-dependent anion channel 2

    2025

    View DOI
    3 cites
  28. Phytochemicals as Therapeutic Agents for ESKAPE Pathogens

    2024

    View DOI
    3 cites
  29. Nitric Oxide Synthase (NOS) Inhibitors in Cancer Angiogenesis

    2015

    View DOI
    3 cites
  30. Predictive Quantitative Structure Toxicity Relationship Study on Avian Toxicity of Some Diverse Agrochemical Pesticides by Monte Carlo Method

    2016

    View DOI
    2 cites
  31. Nipah virus encephalitis: A cause for concern for Indian neurologists?

    2006

    View DOI
    2 cites
  32. 2 cites
  33. Applications of Predictive QSPR Modeling for Deep Eutectic Solvents

    2025

    View DOI
    1 cites
  34. Genetic algorithm-<i>de novo</i>, molecular dynamics and MMGBSA based modelling of a novel Benz-pyrazole based anticancer ligand to functionally revert mutant P53 into wild type P53

    2023

    View DOI
    1 cites
  35. Pharmacovigilance of Herbal Medicines for Lifestyle Diseases

    2023

    View DOI
    1 cites
  36. Evaluation of endurance ability among football players

    2022

    View DOI
    1 cites
  37. Rational design of derivatives and analogs of phenylacetyl isoglutamine synthesis biological activity and molecular modeling

    2015

    1 cites
  38. Epstein–Barr Virus and Treatment of Its Infection

    2014

    View DOI
    1 cites
  39. Multi-scale in-silico modelling to unveil structural requirements for DNA-PK inhibitors as radiosensitizers and MolSHAP based design of novel ligands

    2025

    View DOI
    0 cites
  40. Role of nanomedicines in type 2 diabetes

    2025

    View DOI
    0 cites
  41. List of contributors

    2025

    View DOI
    0 cites
  42. Nanomedicines to alleviate hepatic metabolic disorders

    2025

    View DOI
    0 cites
  43. Nanotechnology for the therapeutic use of biologics to treat metabolic disorders

    2025

    View DOI
    0 cites
  44. Prebiotics and Probiotics in Alzheimer’s Disease

    2025

    View DOI
    0 cites
  45. Preclinical Evaluation of Thrombocytopenic Activity of Hydro-Alcoholic Extract of Psidium guajava L. Fruits on Wistar Rats with in silico Modelling on Dengue Virus Protease Inhibitors

    2025

    View DOI
    0 cites
  46. Targeting Nafld and Nash with Tinospora Crispa: Insights from Network Pharmacology and Molecular Dynamics

    2025

    View DOI
    0 cites
  47. Membrane-disrupting antibacterial activity of Artocarpus lacucha bark extract: a mechanistic study through experimental and computational approaches

    2025

    View DOI
    0 cites
  48. Biological cellular structures used in biosensors

    2025

    View DOI
    0 cites
  49. Contributors

    2025

    View DOI
    0 cites
  50. Mapping Mitochondrial Channel Toxicity: A Case Study for Predicting Mito-Target Interactions for the Per- and Poly-Fluoroalkyl Compounds on the Zebrafish Voltage-Dependent Anion Channel 2

    2024

    View DOI
    0 cites
  51. SMILES-Based Bioactivity Descriptors to Model the Anti-dengue Virus Activity: A Case Study

    2023

    View DOI
    0 cites
  52. Comparative analysis of selected physical fitness components among team game players

    2022

    View DOI
    0 cites
  53. Modelling and molecular dynamics simulation of novel anticancer ligand for restructuring mutant P53 into wild type

    2022

    View DOI
    0 cites
  54. A multi-target in silico model for anti haematological cancers drugs discovery.

    2021

    0 cites
  55. A multi-target &amp;lt;em&amp;gt;in silico&amp;lt;/em&amp;gt; model for anti haematological cancers drugs discovery.

    2021

    View DOI
    0 cites
  56. Chemometric Modeling of Daphnia Toxicity

    2021

    View DOI
    0 cites
  57. Additional file 4 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

    2021

    View DOI
    0 cites
  58. Additional file 3 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

    2021

    View DOI
    0 cites
  59. Additional file 2 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

    2021

    View DOI
    0 cites
  60. Additional file 5 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

    2021

    View DOI
    0 cites
  61. Synthesis, biological evaluation, and enzyme assay of some 5-N-substituted-2-N- (arylsulphonyl)-L(+)glutamines as potential anticancer agents

    2020

    View DOI
    0 cites
  62. Development of Nitric Oxide Synthase (NOS) Inhibitors for Cancer Angiogenesis

    2015

    View DOI
    0 cites
  63. Nitric oxide synthase (NOS) inhibitors in cancer angiogenesis

    Current Enzyme Inhibition1970journal article

    0 cites
  64. Nitric oxide synthase (NOS) inhibitors in cancer angiogenesis

    Current Enzyme Inhibition1970journal article

    0 cites
  65. Recent advances in multi-task QSAR modeling for drug design

    Pharmaceutical Sciences1970journal article

    View DOI
    0 cites
  66. QSAR study on coumarins as antimeningoencephalitic agents

    Internet Electronic Journal of Molecular Design1970journal article

    0 cites
  67. QSAR study on coumarins as antimeningoencephalitic agents

    Internet Electronic Journal of Molecular Design1970journal article

    0 cites
  68. QSAR study on coumarins as antimeningoencephalitic agents

    Internet Electronic Journal of Molecular Design1970journal article

    0 cites
  69. QSAR study on coumarins as antimeningoencephalitic agents

    Internet Electronic Journal of Molecular Design1970journal article

    0 cites
  70. 0 cites
  71. 0 cites